[go: up one dir, main page]

ATE388146T1 - 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor - Google Patents

1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor

Info

Publication number
ATE388146T1
ATE388146T1 AT05702333T AT05702333T ATE388146T1 AT E388146 T1 ATE388146 T1 AT E388146T1 AT 05702333 T AT05702333 T AT 05702333T AT 05702333 T AT05702333 T AT 05702333T AT E388146 T1 ATE388146 T1 AT E388146T1
Authority
AT
Austria
Prior art keywords
carbon atoms
receptor
dihydropyridine
oxo
isopropyl
Prior art date
Application number
AT05702333T
Other languages
English (en)
Inventor
Chikara Uchida
Kiyoshi Kawamura
Tomoki Kato
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Application granted granted Critical
Publication of ATE388146T1 publication Critical patent/ATE388146T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10Laxatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychiatry (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Nutrition Science (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT05702333T 2004-01-29 2005-01-18 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor ATE388146T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54014304P 2004-01-29 2004-01-29

Publications (1)

Publication Number Publication Date
ATE388146T1 true ATE388146T1 (de) 2008-03-15

Family

ID=34826191

Family Applications (1)

Application Number Title Priority Date Filing Date
AT05702333T ATE388146T1 (de) 2004-01-29 2005-01-18 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor

Country Status (9)

Country Link
US (2) US7691881B2 (de)
EP (1) EP1713797B1 (de)
JP (1) JP4859672B2 (de)
AT (1) ATE388146T1 (de)
BR (1) BRPI0507180A (de)
CA (1) CA2555258C (de)
DE (1) DE602005005167T2 (de)
ES (1) ES2299995T3 (de)
WO (1) WO2005073222A1 (de)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200533348A (en) 2004-02-18 2005-10-16 Theravance Inc Indazole-carboxamide compounds as 5-ht4 receptor agonists
US7728006B2 (en) 2004-04-07 2010-06-01 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
TWI351282B (en) 2004-04-07 2011-11-01 Theravance Inc Quinolinone-carboxamide compounds as 5-ht4 recepto
US8309575B2 (en) 2004-04-07 2012-11-13 Theravance, Inc. Quinolinone-carboxamide compounds as 5-HT4 receptor agonists
JP5042028B2 (ja) 2004-11-05 2012-10-03 セラヴァンス, インコーポレーテッド キノリノン−カルボキサミド化合物
ES2332808T3 (es) 2004-11-05 2010-02-12 Theravance, Inc. Compuestos agonistas del receptor 5-ht4.
MX2007007818A (es) 2004-12-22 2007-09-11 Theravance Inc Compuestos de indazol-carboxamida.
KR20070107807A (ko) 2005-03-02 2007-11-07 세라밴스 인코포레이티드 5-ht4 수용체 아고니스트인 퀴놀리논 화합물
US7728013B2 (en) 2005-05-10 2010-06-01 Intermune, Inc. Method of modulating stress-activated protein kinase system
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
AU2006327313A1 (en) * 2005-12-23 2007-06-28 Astrazeneca Ab Heterocyclic GABA-B modulators
CN101668744A (zh) * 2006-12-27 2010-03-10 盐野义制药株式会社 1-取代-2-吡啶酮-3-甲酸衍生物的制备方法
ES2567283T3 (es) 2008-06-03 2016-04-21 Intermune, Inc. Compuestos y métodos para tratar trastornos inflamatorios y fibróticos
US8642772B2 (en) 2008-10-14 2014-02-04 Sk Biopharmaceuticals Co., Ltd. Piperidine compounds, pharmaceutical composition comprising the same and its use
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
WO2011095450A1 (en) 2010-02-02 2011-08-11 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
WO2011099305A1 (en) * 2010-02-12 2011-08-18 Raqualia Pharma Inc. 5-ht4 receptor agonists for the treatment of dementia
US10905652B2 (en) 2011-03-23 2021-02-02 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9498447B2 (en) 2011-03-23 2016-11-22 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8927010B2 (en) 2011-03-23 2015-01-06 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8916588B2 (en) 2011-03-23 2014-12-23 Ironshore Pharmaceuticals & Development, Inc. Methods for treatment of attention deficit hyperactivity disorder
PT2688557T (pt) 2011-03-23 2017-11-23 Ironshore Pharmaceuticals & Dev Inc Métodos e composições para o tratamento de distúrbio de défice de atenção
US11241391B2 (en) 2011-03-23 2022-02-08 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US10292937B2 (en) 2011-03-23 2019-05-21 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9119809B2 (en) 2011-03-23 2015-09-01 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US9603809B2 (en) 2011-03-23 2017-03-28 Ironshore Pharmaceuticals & Development, Inc. Methods of treatment of attention deficit hyperactivity disorder
US9283214B2 (en) 2011-03-23 2016-03-15 Ironshore Pharmaceuticals & Development, Inc. Compositions for treatment of attention deficit hyperactivity disorder
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
CA2867043A1 (en) 2012-05-03 2013-11-07 Novartis Ag L-malate salt of 2,7-diaza-spiro[4.5]dec-7-yle derivatives and crystalline forms thereof as ghrelin receptor agonists
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
CA2943363A1 (en) 2014-04-02 2015-10-08 Intermune, Inc. Anti-fibrotic pyridinones

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9305947A (es) * 1992-09-29 1994-06-30 Smithkline Beecham Plc Compuestos antagonistas del receptor 5-ht4, procedimiento para su preparacion y composiciones farmaceuticas que las contienen.
TW402591B (en) 1997-07-11 2000-08-21 Janssen Pharmaceutica Nv Monocyclic benzamides of 3- or 4-substituted 4-(aminomethyl)-piperidine derivatives
MXPA03000145A (es) * 2002-01-07 2003-07-15 Pfizer Compuestos de oxo u oxi-piridina como moduladores de receptores 5-ht4.

Also Published As

Publication number Publication date
JP2007519708A (ja) 2007-07-19
BRPI0507180A (pt) 2007-06-26
ES2299995T3 (es) 2008-06-01
US20100144789A1 (en) 2010-06-10
CA2555258A1 (en) 2005-08-11
DE602005005167T2 (de) 2009-04-30
WO2005073222A1 (en) 2005-08-11
US20080293767A1 (en) 2008-11-27
EP1713797A1 (de) 2006-10-25
US8362038B2 (en) 2013-01-29
CA2555258C (en) 2009-04-28
EP1713797B1 (de) 2008-03-05
DE602005005167D1 (de) 2008-04-17
US7691881B2 (en) 2010-04-06
JP4859672B2 (ja) 2012-01-25

Similar Documents

Publication Publication Date Title
ATE388146T1 (de) 1-isopropyl-2-oxo-1,2-dihydropyridin-3- carbonsäureamidderivate mit agonistischer wirkung am 5-ht4-rezeptor
CY1107008T1 (el) Παραγωγο βενζιμιδαζολης και χρηση ως ανταγωνιστου υποδοχεα aii
NO20071642L (no) N-Benzensulfonylsubstituerte anilino-pyrimidinanaloger
DOP2003000703A (es) Compuestos de imidazopiradina como agonistas del receptor 5-ht4
TW200604175A (en) Ortho substituted aryl or heteroaryl amide compounds
NO20082934L (no) Antivirale nukleotider
EA201101089A1 (ru) Производные оксадиазола в качестве агонистов рецептора s1p1
WO2005105732A8 (en) Substituted methyl aryl or heteroaryl amide compounds
DE602006007012D1 (de) Pyridinderivate als dipeptedyl-peptidase-hemmer
EP1325921A3 (de) Oxo oder Oxy-pyridine als 5-HT4 Rezeptor-Modulatoren
CA2536870A1 (en) Phenyl or pyridyl amide compounds as prostaglandin e2 antagonists
NO20081821L (no) Forbindelser for behandling av metabolske forstyrrelser
BRPI0615111B8 (pt) composto, composição farmacêutica, e, uso do composto
EA200800476A1 (ru) Макроциклические ингибиторы вируса гепатита с
NO20050418L (no) Kondenserte pyridiner og pyrimidiner med TIE2(TEK) aktivitet
ATE461192T1 (de) Chinoloncarbonsäureverbindungen mit 5-ht4- rezeptoragonistischer wirkung
NO20082136L (no) 1,5-substituerte indol-2-yl-amidderivater
EA200971080A1 (ru) Кристаллическое соединение пиридазина
WO2004094418A8 (en) Imidazopyridine compounds having 5-ht4 receptor agonistic activity and 5-ht3 receptor antagonistic activity
NO20075617L (no) 4-fenyl-5-okso-1,4,5,6,7,8-heksahydrokinolinderivater for behandling av infertilitet
BR0213026A (pt) Compostos de imidazopiridina como reguladores do receptor 5-ht4
EA200970555A1 (ru) Трициклическое соединение и его медицинское применение
TNSN07439A1 (en) Derivatives of,4,5 - diarylpyrrole, preparation method thereof and use of same in therapeutics
NO20081220L (no) Nytt cercosporamidderivat
ATE445619T1 (de) Pyridinylpyrazolopyrimidinon-derivate als pde 7 inhibitoren

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties